We conducted a randomized , parallel-group , double-blind , placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin ( 24 , 48 , or 72 IU ) administered twice daily for 1 week to 23 patients with behavioral variant FTD or semantic dementia ( clinicaltrials.gov registration number NCT01386333 ) .